ABT — ABBOTT LABORATORIES

Health Care

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying ABT?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
80
Institutional Conviction
Strong distribution · 1 buying vs 4 selling last quarter
21
Macro Tailwind
Macro conditions are a headwind for Health Care
36
Congressional Activity
2 congressional purchases, 2 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 5 tracked investors who changed their ABT position last quarter, 1 bought and 4 sold (20% buy-side). Macro conditions are a headwind for Health Care (Macro Tailwind 36/100 in a Expansion regime). 2 congressional purchases, 2 sales disclosed in the last 6 months.

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Steve Cohen)
  • +5 tracked investors reported holding ABT at their latest filing
  • +2 congressional purchases disclosed in the last 6 months
Contradicting evidence — always shown
  • −4 tracked investors reduced or exited last quarter (4 reduced, 0 sold out)
  • −Current Expansion regime has historically been a headwind for Health Care (Macro Tailwind 36/100)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.

About ABBOTT LABORATORIES (ABT)

ABBOTT LABORATORIES (ABT) appears in the most recent 13F filings of 5 tracked institutional investors. ABBOTT LABORATORIES is classified in the Health Care sector. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $1.1B. Across recent filings, tracked investors recorded 7 new positions, 15 increased, 25 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in ABT

45
/100
Mixed Activity
Added / Increased22
Reduced25
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track ABT

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

ABT Ownership Composition

How ABBOTT LABORATORIES is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
97% of tracked value
Institutions
5
tracked investors
Total Reported
$1.1B
combined 13F value
Types2
  • Multi-Strategy / Quant97.2%
  • Macro2.8%
Multi-Strategy / Quant(3)
97.2%
Macro(2)
2.8%

Tracked investors currently reporting ABT

1 tracked investor has since exited this position — listed separately below.

  • Ken GriffinSep 30, 2026
    Citadel Advisors
    Shares
    5.3M
    Value
    $520.7M
    % Portfolio
    0.06%
  • Izzy EnglanderSep 30, 2026
    Millennium Management
    Shares
    3.2M
    Value
    $316.4M
    % Portfolio
    0.10%
  • Steve CohenSep 30, 2026
    Point72 Asset Management
    Shares
    2.4M
    Value
    $239.2M
    % Portfolio
    0.27%
  • Ray DalioSep 30, 2026
    Bridgewater Associates
    Shares
    55.8K
    Value
    $5.5M
    % Portfolio
    0.02%
  • Paul Tudor JonesSep 30, 2026
    Tudor Investment Corp
    Shares
    260.3K
    Value
    $25.7M
    % Portfolio
    0.03%

Previously held ABT

These investors reported ABT in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
George SorosSoros Fund Management44.8K$4.6MMar 31, 2026

Recent activity

Frequently asked questions

How many institutional investors hold ABT?
5 tracked institutional investors disclosed a position in ABT (ABBOTT LABORATORIES) in their most recent 13F filing.
Who is the largest institutional holder of ABT?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in ABT, valued at $1.1B.
Did institutional ownership of ABT increase or decrease?
Across recent 13F filings, tracked investors recorded 7 new positions, 15 increased, 25 reduced, and 2 fully exited ABT.
What sector is ABT in?
ABBOTT LABORATORIES is classified in the Health Care GICS sector.
Where does this ABT ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
ABT (ABBOTT LABORATORIES) — Institutional Holders & 13F — InvestorLens